BCYC - Bicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05 revenue of $3.04M misses by $2.54M
- Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q3 GAAP EPS of -$0.96 misses by $0.05 .
- Revenue of $3.04M (-29.8% Y/Y) misses by $2.54M .
-
Cash and cash equivalents of $361.5 million as of September 30, 2022; expected financial runway into 2025
- Research and development expenses were $22.8 million for the three months ended September 30, 2022, compared to $10.5 million for the three months ended September 30, 2021.
For further details see:
Bicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05, revenue of $3.04M misses by $2.54M